Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure: A Review | Chapter 1 | Current Practice in Medical Science Vol. 3

When the heart fails, it is unable to produce enough energy, leaving the body in an energy-starved state with reduced functioning. Numerous modifications to the metabolic pathways in the failing heart that result in a decrease in the oxidation of either glucose or fatty acid substrates have been found in studies. Diminished energy production is needed to mediate cardiac contraction as a result of this reduced oxidation, which results from abnormalities in mitochondrial activities and/or oxidative phosphorylation. Early-stage clinical studies have demonstrated that fatty acid oxidation inhibitors and antioxidants that target the mitochondria improve cardiac function during failure by increasing compensatory glucose oxidation. Adrenergic receptors (α₁ and β) are a crucial regulator of the sympathetic nervous system that controls heart function. Both β-AR blockers and α-_1A-AR agonists have potential therapeutic use in the treatment of heart failure. In addition to regulating inotropy and chronotropy, the heart's α¹- and β2-adrenergic receptors also regulate metabolic processes that have a positive impact on the heart. In this review, we highlight new research that show how metabolic pathways regulated by adrenergic receptors may be able to restore cardiac energetics to non-failing levels, suggesting potential treatment approaches.

Author(s) Details:

Dianne M. Perez,

The Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, US.

Please see the link here: https://stm.bookpi.org/CPMS-V3/article/view/7379